and Human Services (HHS)
EXPIRED
Department of Health and Human Services
Participating Organizations
National
Institutes of Health (NIH), ( http://www.nih.gov)
Components of Participating Organizations
National Heart, Lung, and
Blood Institute (NHLBI), ( http://www.nhlbi.nih.gov/)
National Center on Sleep Disorders Research (NCSDR), (http://www.nhlbi.nih.gov/sleep)
National Institute on Aging (NIA), (http://www.nia.nih.gov/)
National Institute on Alcohol Abuse and Alcoholism (NIAAA), (http://www.niaaa.nih.gov/)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),
(http://www.niams.nih.gov/)
National Cancer Institute (NCI), (http://www.nci.nih.gov/)
National Institute of Child Health and Human Development (NICHD), (http://www.nichd.nih.gov/)
National Center for Complementary and Alternative Medicine (NCCAM), (http://www.nccam.nih.gov/)
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov/)
National Institute of Mental Health (NIMH), (http://www.nimh.nih.gov/)
National Institute of Neurological Disorders and Stroke (NINDS), (http://www.ninds.nih.gov/)
National Institute of Nursing Research (NINR), (http://www.ninr.nih.gov/)
Office of Research on Women's Health (ORWH), (http://www4.od.nih.gov/orwh/)
Title: Research on Sleep and Sleep Disorders (R21)
Announcement Type
This is a reissue of PA-05-046 which was previously released February 9, 2005.
Update: The following update relating to this announcement has been issued:
NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and SF424 (R&R) Application Guide. APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.
This FOA must be read in conjunction with the application guidelines provided with this announcement in Grants.gov/Apply for Grants (hereafter called Grants.gov/Apply).
A registration process is necessary before submission and applicants are highly encouraged to start the process at least four weeks prior to the grant submission date. See Section IV.
Two steps are required for on time submission:
1) The application must be submitted to Grants.gov by 5:00 p.m. local time (of the applicant institution/organization) on the submission date (see Key Dates below).
2) Applicants must complete a verification step in the eRA Commons within two business days of notification from NIH. Note: Since email can be unreliable, it is the responsibility of the applicant to periodically check on their application status in the Commons.
Program Announcement (PA) Number: PA-06-238
Catalog of Federal Domestic Assistance
Number(s)
93.866,
93.273, 93.846, 93.864, 93.279, 93.233, 93.242, 93.853, 93.361, 93.213, 93.865
Key Dates
Release/Posted Date:
March 16, 2006
Opening
Date: May 2, 2006 (Earliest date an
application may be submitted to Grants.gov)
Letter of
Intent Receipt Date(s): Not applicable
Application Submission Date(s): Standard dates apply, please see
http://grants1.nih.gov/grants/funding/submissionschedule.htm
AIDS Application Submission Date(s): http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS.
Peer
Review Date(s): http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward.
Council Review Date(s): http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Earliest
Anticipated Start Date: http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward.
Additional Information To Be Available Date (URL Activation Date): Not
Applicable
Expiration
Date: September 2, 2008 (now September 8, 2008 per NOT-OD-07-093)
Due Dates for E.O. 12372
Not Applicable
Additional Overview
Content
Executive Summary
As summarized in the 2003 National Sleep Disorders Research Plan (http://www.nhlbi.nih.gov/health/prof/sleep/res_plan/index.html), multiple scientific areas in sleep and sleep disorders need additional research. In addition, therapy for a number of sleep disorders remains suboptimal, and the research workforce addressing sleep science is insufficient. The NHLBI, National Center on Sleep Disorders Research, and co-sponsoring member Institutes and Centers of the Trans-NIH Sleep Research Coordinating Committee therefore invite submission of grant applications proposing research to advance biomedical knowledge related to sleep or sleep disorders, improve understanding of the neurobiology or functions of sleep over the life-span, enhance timely diagnosis and effective treatment for individuals affected by sleep-related disorders, or implement and evaluate innovative community-based public health education and intervention programs.
Table of Contents
Part I Overview Information
Part
II Full Text of Announcement
Section
I. Funding Opportunity Description
1. Research
Objectives
Section
II. Award Information
1. Mechanism of
Support
2. Funds Available
Section
III. Eligibility Information
1. Eligible
Applicants
A.
Eligible Institutions
B.
Eligible Individuals
2. Cost Sharing or
Matching
3. Other - Special
Eligibility Criteria
Section
IV. Application and Submission Information
1. Request
Application Information
2. Content and Form
of Application Submission
3. Submission Dates
and Times
A.
Submission, Review and Anticipated Start Dates
1. Letter of Intent
B.
Sending an Application to the NIH
C.
Application Processing
4. Intergovernmental
Review
5. Funding
Restrictions
6. Other Submission
Requirements
Section
V. Application Review Information
1. Criteria
2. Review and
Selection Process
A. Additional
Review Criteria
B.
Additional Review Considerations
C.
Sharing Research Data
D.
Sharing Research Resources
3. Anticipated
Announcement and Award Dates
Section
VI. Award Administration Information
1. Award Notices
2. Administrative
and National Policy Requirements
3. Reporting
Section
VII. Agency Contact(s)
1.
Scientific/Research Contact(s)
2. Peer Review
Contact(s)
3. Financial/ Grants
Management Contact(s)
Section VIII. Other Information - Required Federal
Citations
Part II
- Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The three broad categories of sleep-related problems include:
An estimated 70 million people in the United States suffer from sleep problems, and more than 50% of them have a chronic sleep disorder. About 30 million American adults have frequent or chronic insomnia. Approximately 18 million have sleep apnea (sleep disordered breathing), but fewer than 50% are presently being diagnosed. An estimated 250,000 people have narcolepsy, and 10 to 20% of adults are affected by restless legs syndrome. According to the National Highway Traffic and Safety Administration (NHTSA), 100,000 accidents and 1,500 traffic fatalities per year are related to drowsy driving. More than 50% of Americans over age 65 have sleep difficulties, and prevalence of sleep problems will therefore increase as the over-65 population increases. Each year, sleep disorders, sleep deprivation, and excessive daytime sleepiness add approximately $16 billion annually to the cost of health care in the U.S., and result in $50 billion annually in lost productivity. In addition to conventional therapies to treat sleep disorders, many individuals use complementary and alternative therapies (CAM). According to the 2002 National Health Interview Survey, approximately 1.6 million adults use CAM specifically for sleep disorders. Sleep problems and disorders have major societal impacts, but have not received sufficient attention in basic and clinical research.
The 2003 National Sleep Disorders Research Plan (www.nhlbi.nih.gov/health/prof/sleep/res_plan/index.html) summarizes current knowledge regarding the neurobiology of sleep and sleep disorders, and concludes with a prioritized listing of recommendations for future research.
We are now beginning to understand the impact of chronic sleep loss or sleeping at adverse circadian times on the ability to function optimally and on physical and mental health. How sleep loss, sleep displacement (e.g., shift work), and a wide range of sleep disorders affect one's ability to maintain health and healthy functioning in a 24/7 world, however, are relatively poorly understood. In addition, with the enhanced lifespan, the growing aging population carries a risk for sleep disturbances caused by greater physical and psychological changes. Thus, despite substantial scientific progress in both clinical and basic science related to sleep and its disorders, there remains the challenge and the need to better understand the functions of sleep, to better understand and treat disorders affecting sleep, and to explain the nature of human physiology during wakefulness and the individual stages of sleep. Without progress in these areas, millions will continue to suffer the consequences of dysfunction and abuse of this most basic regulatory process.
Sleep Neurobiology:
The discovery of hypocretin/orexin and its role in the
development of narcolepsy in animal models and in humans revolutionized our
understanding of this debilitating disorder and promises important advances in
the diagnosis and therapy of human narcolepsy. However, we need to better
understand the neuromodulatory role of hypocretin/orexin and improve our
understanding of the basic neurobiological processes that control sleep and
wakefulness. New anatomical and physiological approaches have led to advances
in our understanding of the location and interconnections between hypothalamic
and brainstem circuits controlling REM, nonREM, and wake states. Factors
regulating the activity of these sleep-controlling neurons have been identified.
Circuitry and neurotransmitter mechanisms controlling muscle tone across the
sleep cycle, of relevance to numerous sleep pathologies, have also been
identified.
Circadian Biology:
A growing number of "clock genes" have been
identified that play a critical role in mammalian circadian timing. In
addition, there is clear evidence that non-suprachiasmatic nucleus (SCN)
tissues have clock genes and can demonstrate circadian rhythms. Thus, circadian
modulation occurs both centrally and peripherally, further emphasizing the
importance of circadian chronobiology in the timing of sleep and waking as well
as a wide variety of physiologic functions. These studies of clock genes also
apply to humans, in particular patients with advanced sleep phase syndrome,
especially prominent in the elderly population. The role of endogenous
melatonin in the sleep/wake cycle has been better defined and the clinical
studies on the role of exogenous melatonin to treat sleep disorders are
ongoing.
Sleep Deprivation:
Previous studies have demonstrated many of the ill effects
of total sleep deprivation, but the impact of chronic partial sleep deprivation
(restriction) has not been extensively investigated even though it is much more
common. Recent studies indicate that 4 to 6 hours of sleep per night yields a
progressive, cumulative deterioration in neurobehavioral function including
vigilance, neurocognitive performance, and mood. This reduction in performance
is also associated with changes in cerebral activation during cognitive tasks.
Physiologic changes also appear to occur, e.g., insulin resistance, increased
sympathetic activation, decreased immune system function, lower core body
temperature, and decreased release of growth hormone. Both the neurocognitive
and physiologic effects of chronic sleep loss suggest there is an optimal sleep
duration and a cost for failing to achieve it. However, the exact duration of
sleep required at different periods of life remains poorly understood, as do
the mechanisms driving these neural and metabolic processes.
Sleep-Disordered Breathing (SDB):
The consequences of SDB (obstructive sleep apnea) have
become increasingly defined over the last few years. In adults, the
contribution of SDB to the development of systemic hypertension is becoming
more evident and data are accumulating that other adverse cardiovascular
outcomes (stroke, congestive heart failure, myocardial infarction) may result
from this disorder. Co-existing obesity can result in structural impairments
impacting airway patency, creating additional cardiovascular problems. In
children, there is increasing evidence that sleep apnea may contribute to
behavioral problems as well as learning and cognitive deficits.
Insomnia:
The high prevalence, risk factors, and consequences of
insomnia are being increasingly defined. Insomnia has been identified as a risk
factor for the onset of subsequent depression, anxiety, and substance use
disorders. In addition, the efficacy and durability of behavioral therapies for
insomnia have been demonstrated in controlled clinical trials.
Sleep in Psychiatric, Alcohol, and Substance
Use Disorders:
Most psychiatric and substance use disorders are associated
with sleep disruption. Alcohol dependence and use of other psychoactive
substances lead to complaints of insomnia and sleep disruption that can persist
for months into recovery. These sleep disturbances may result in continued
alcohol and/or drug use to alleviate symptoms, and thereby precipitate relapse.
Psychiatric disorders can also be associated with daytime sleepiness, fatigue,
abnormal circadian sleep patterns, disturbing dreams and nightmares.
Conversely, increasing evidence suggests that primary insomnia (without
concurrent psychiatric disorder) is a risk factor for later developing
psychiatric disorders, particularly depression, anxiety, and substance use
disorders.
Most progress has been related to associations between psychiatric disorders and various sleep symptoms (e.g., insomnia and nightmares), sleep EEG patterns (e.g., delta EEG activity), and sleep disorders. Less progress has been made in identifying fundamental pathophysiological mechanisms linking psychiatric disorders and sleep. Sensitive and specific sleep biomarkers of psychiatric disorders, for example, have not been validated. Similarly, endogenous circadian rhythm disturbances have not been identified in most patients with depression or other psychiatric disorders. Little is known about characteristics or consequences of sleep disturbances in most childhood psychiatric disorders, in children of alcohol or substance abusing mothers, or in children at high risk for developing psychiatric and alcohol/substance abuse disorders. The application of sleep and circadian rhythm therapies to psychiatric disorders has been limited, and their efficacy not consistently demonstrated.
Clinical neuroscience studies are needed to investigate the common mechanisms and consequences of disordered sleep (e.g., immune dysfunction) in psychiatric and alcohol/substance dependent populations. Insomnia and sleep disturbances are risk factors for psychiatric disorders including alcohol dependence, but long-term follow-up studies have not yet been done to determine whether intervention can reduce these risks and the progression of these disorders.
Pediatrics:
Recent research regarding the physiologic, psychological
and developmental aspects of sleep in infants, children, and adolescents has
contributed to an increased understanding of the unique aspects of sleep and
development. The study of pediatric disorders such as Congenital Central
Hypoventilation Syndrome and Rett Syndrome has led to a better basic
understanding of autonomic regulation and respiratory control. Recent findings
regarding the complex relationship between sleep patterns and hormonal changes
in adolescence have broadened our understanding of pubertal influences on sleep
and circadian biology. The extent of sleep restriction and sleep disturbances
among children and adolescents is much greater than previously believed, and
the consequent impact on mood, neurobehavioral and academic functioning,
safety, and health is considerable. Recognition of the link between sleep
disturbances and neurobehavioral disorders in childhood, such as attention
deficit hyperactivity disorder (ADHD), has major public health implications for
both the treatment and prevention of psychiatric co-morbidity.
Sleep Education:
A variety of recently implemented educational activities
have substantial potential impact on sleep literacy and public health. We need
to consolidate and extend the research progress made to date, and to translate
new knowledge into effective therapies and community-based dissemination and
implementation programs in order to apply what is known to improve public
health and quality of life.
Complementary and Alternative Medical Therapies
for Sleep Disorders:
Many individuals use c complementary and alternative
medical (CAM) therapies for sleep disorders. These therapies are often already
in the public domain, but have only recently been subjected to rigorous basic
and clinical research to determine efficacy, effectiveness, and mechanisms of
action. Ongoing research is determining efficacy of natural products such as
valerian and melatonin for specific sleep disorders. Other CAM approaches such
as meditation, yoga, and light therapy are also being investigated for their
role in improving sleep. Programs to educate health practitioners about the
potential role of evidenced-base CAM therapies for treating sleep disorders
will in turn aid in educating the public about both the benefits and risks of CAM therapies.
Sleep in Chronic Pain and Rheumatologic
Disorders:
Sleep and changes in sleep are related to various cellular,
hormonal, and immunological functions. Pain and other components of disease may
influence the sleep process and alter these parameters, thereby interacting
with the disease process. Correspondingly, many of the daytime symptoms in
patients with rheumatic diseases pain, stiffness, fatigue, and cognitive
dysfunction may be linked to non-restorative sleep patterns associated with
these diseases. Research is needed on the role of sleep, and the bi-directional
interactions between sleep and disease processes, in rheumatic diseases in
humans and animal models. Studies on effects of sleep and sleep dysfunction on
relevant physiological processes, and on disease progression, symptoms, and
daily functioning are needed. Effects of disease treatment (e.g., TNF alpha) on
sleep should be investigated. In addition, changes in disease-relevant
parameters following intervention studies targeting sleep or experimental
manipulation of sleep should be investigated, as should the relationship
between sleep and pain, especially in fibromyalgia.
Topics for research that would be responsive to this FOA include, but are not limited to:
Neurobiology and functions of sleep and neurochemistry of sleep/wake generating systems from fetal life across the full age spectrum, including molecular, biochemical, anatomic and physiologic investigations. Explore sex differences in these systems.
Exploration of the physiologic basis for the restorative function of sleep in maintenance of health.
Basic research on hypocretins to better define the exact role of this system in the regulation of normal sleep and other behaviors.
Neurobiological mechanisms of the effects of sleep, circadian regulation, sleep homeostasis, and sleep disorders on the aging process and the diseases associated with late age.
Methods to measure sleep, circadian physiology, and sleepiness across the age spectrum, including methods used in the home.
Psychological, behavioral , neurobiological, and physiological consequences and underlying mechanisms of long-term partial sleep deprivation from childhood through old age.
Recovery patterns following chronic partial sleep loss and whether rates of recovery vary by age and/or for physiological, behavioral and cognitive processes; identification of factors that facilitate recovery and minimize long-term adverse consequences.
Epidemiologic, behavioral, physiologic or neurobiological studies addressing relationships between the processes of sleep and the development and progression of both neural and non-neural diseases.
Studies of the mechanisms by which sleep disturbances affect adherence to treatments for chronic disease and ways that improving sleep may improve treatment outcomes.
Improved understanding of the processes that lead to specific sleep disorders in infants, children, and adults, including the aged population. Explicate sex differences in these processes.
Interventions to help children and adults adapt to the sleep disturbance associated with homes, hospitals, critical care settings, and nursing homes
Studies of sleep disturbance in children and adolescents as a risk factor for the early onset of drinking, and the development of alcohol abuse and dependence.
Studies of insomnia and hypersomnia as modifiable risk factors for poor outcomes in mood, anxiety, and psychotic disorders, alcoholism, and substance abuse disorders, including whether interventions
can prevent progression of these disorders and reduce risk for relapse in the alcohol and substance abuse disorders.
Impact of sleep-disordered breathing (SDB) and its treatment on functional status, psychiatric disorders, neurocognitive function and behavior, and other disease processes.
Studies of disorders leading to hypersomnolence or neural mechanisms leading to hypersomnolence in conditions such as narcolepsy or primary central nervous system hypersomnolence, and how these mechanisms may differ from or resemble the effects of sleep loss.
Studies of normal human sleep phenotypes and the normal range of variation in children, adults and the aged (including racial and ethnic disparities), and quantitative assessment of sleep variables such as duration, sleep stage distribution and sleep quality.
Studies of sleep problems and disorders in children related to chronic maternal use of alcohol, cigarette smoking, and narcotic drugs.
Interrelationships between sleep and neuroendocrine systems, including aging male and female populations.
Studies of the role of cytokines in sleep regulation in psychiatric populations also at risk for infectious or inflammatory disorders, and studies of cytokine antagonists in sleep-disturbed alcohol using populations with evidence of immune activation.
New treatments for sleep disorders, including methods to adapt these therapies to individual patients using approaches such as pharmacogenetics.
Basic and clinical research on complementary and alternative medicine (CAM) therapies for sleep disorders. These could include, but are not limited to mind/body therapies such as yoga and meditation; biological based therapies such as herbal medicine; manipulative therapies such as chiropractic manipulation; energy medicine such as Reiki and Qi gong; and therapies based on traditional medical systems such as Traditional Chinese Medicine or naturopathic medicine.
Assessment of outcomes of sleep disorder therapies, including CAM therapies, at all levels including efficacy, adherence, effectiveness, morbidity, quality of life, health care costs, safety, and performance/productivity.
Impact of sleep educational programs related to healthy sleep habits and sleep literacy or to improved rates of diagnosis and treatment of sleep disorders.
Assessment of physician and other health care provider knowledge of sleep disorders and current treatment options, both CAM and conventional.
Applications of informatics to clinical, neurophysiologic, imaging, and genetic studies as they apply to sleep and its disorders.
Neurophysiology of sleep regulation affecting risk for and mechanisms of sleep disorders in women in relation to menarche, pregnancy, or menopause.
Neurophysiological and neuroanatomical correlates and gene-environment interactions contributing to racial and ethnic disparities in prevalence and severity of individual sleep disorders, and strategies to better inform racial and ethnic minority populations about sleep-related conditions through public health education programs.
Sleep in neurodegenerative disorders including but not restricted to Parkinson's disease.
Sleep in neuropathic pain conditions.
Explicate the role of menopause and pregnancy in sleep disorders.
Explore the preponderance of women in many of the multisystemic conditions associated with sleep disorders.
See Section VIII, Other Information - Required Federal
Citations, for policies related to this announcement.
Section II. Award Information
1. Mechanism of Support
This funding opportunity will use the National Institutes of Health (NIH) Exploratory/Developmental Research Grant (R21). As an applicant, you will be solely responsible for planning, directing, and executing the proposed project.
This funding opportunity uses just-in-time concepts. It also uses the modular budget formats (see the Modular Applications and Awards section of the NIH Grants Policy Statement. Specifically, if you are submitting an application with direct costs in each year of $250,000 or less (excluding consortium Facilities and Administrative [F&A] costs), use the PHS398 Modular Budget component provided in the SF424 (R&R) Application Package and SF424 (R&R) Application Guide (see specifically Section 5.4, Modular Budget Component, of the Application Guide).
Exploratory/developmental grant support is for new projects only; competing renewal (formerly competing continuation ) applications will not be accepted. Up to two resubmissions (formerly revisions/amendments") of a previously reviewed exploratory/developmental grant application may be submitted. See NOT-OD-03-041, May 7, 2003.
2. Funds Available
Because the nature
and scope of the proposed research will vary from application to application,
it is anticipated that the size and duration of each award will also vary.
Although the financial plans of the Institutes and Centers (ICs) provide
support for this program, awards pursuant to this funding opportunity are
contingent upon the availability of funds and the submission of a sufficient
number of meritorious applications. .
The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over the two years of the R21 award, with no more than $200,000 in direct costs allowed in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this Program Announcement funding opportunity.
Facilities and administrative (F&A) costs requested by consortium
participants are not included in the direct cost limitation. See NOT-OD-05-004.
Section
III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
You may submit (an)
application(s) if your organization has any of the following characteristics:
1.B.
Eligible Individuals
Any individual with the
skills, knowledge, and resources necessary to carry out the proposed research
is invited to work with their institution to develop an application for
support. Individuals from underrepresented racial and ethnic groups as well as
individuals with disabilities are always encouraged to apply for NIH programs.
2. Cost Sharing or Matching
This program does not require cost
sharing as defined in the current NIH
Grants Policy Statement.
3. Other-Special Eligibility Criteria
Applicants
may submit more than one application, provided each application is
scientifically distinct.
Section IV. Application and Submission Information
Registration and Instructions for Submission via Grants.gov
To download a SF424 (R&R) Application Package and
SF424 (R&R) Application Guide for completing the SF424 (R&R) forms for
this FOA, link to http://www.grants.gov/Apply/ and follow the directions provided on that Web site.
A one-time registration is required for institutions/organizations at both:
PD/PIs should work with their institutions/organizations to make sure they are registered in the NIH Commons.
Several additional separate actions are required before an applicant institution/organization can submit an electronic application, as follows:
1) Organizational/Institutional Registration in Grants.gov/Get Started
2) Organizational/Institutional Registration in the eRA Commons
3) Project Director/Principal Investigator (PD/PI) Registration in the NIH eRA Commons: Refer to the NIH eRA Commons System (COM) Users Guide.
Note that if a PD/PI is also an NIH peer-reviewer with an Individual DUNS and CCR registration, that particular DUNS number and CCR registration are for the individual reviewer only. These are different than any DUNS number and CCR registration used by an applicant organization. Individual DUNS and CCR registration should be used only for the purposes of personal reimbursement and should not be used on any grant applications submitted to the Federal Government.
Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their institution is already registered in both Grants.gov and the Commons. The NIH will accept electronic applications only from organizations that have completed all necessary registrations.
1.
Request Application Information
Applicants
must download the SF424 (R&R) application forms and SF424 (R&R)
Application Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached to a
specific FOA can be used. You will not be able to use any other SF424 (R&R)
forms (e.g., sample forms, forms from another FOA), although some of the
"Attachment" files may be useable for more than one FOA.
For further
assistance contact GrantsInfo, Telephone 301-710-0267, Email: [email protected].
Telecommunications
for the hearing impaired: TTY 301-451-5936.
2. Content and Form of
Application Submission
Prepare all applications using the SF424
(R &R) application forms and in accordance with the SF424 (R&R) Application Guide (MS Word or PDF).
The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to NIH. There are fields within the SF424 (R&R) application components that, although not marked as mandatory, are required by NIH (e.g., the Credential log-in field of the Research & Related Senior/Key Person Profile component must contain the PD/PI’s assigned eRA Commons User ID). Agency-specific instructions for such fields are clearly identified in the Application Guide. For additional information, see Tips and Tools for Navigating Electronic Submission on the front page of Electronic Submission of Grant Applications.
The SF424 (R&R) application is comprised of data arranged in separate components. Some components are required, others are optional. The forms package associated with this FOA in Grants.gov/ APPLY will include all applicable components, required and optional. A completed application in response to this FOA will include the following components:
Required Components:
SF424
(R&R) (Cover component)
Research & Related Project/Performance Site Locations
Research
& Related Other Project Information
Research
& Related Senior/Key Person
PHS398
Cover Page Supplement
PHS398
Research Plan
PHS398
Checklist
PHS398 Modular Budget
Optional Components:
PHS398
Cover Letter File
R&R
Subaward Budget Attachment(s) Form
Note: While both budget components are included in the SF424 (R&R) forms package, the NIH R21 uses ONLY the PHS 398 Modular Budget. (Do not use the detailed Research & Related Budget.)
Foreign
Organizations
Several
special provisions apply to applications submitted by foreign organizations:
Proposed research should provide a unique research
opportunity not available in the United States.
3. Submission Dates and Times
See Section IV.3.A for details.
3.A. Submission, Review
and Anticipated Start Dates
Opening Date: May 2, 2006 (Earliest date an application may be
submitted to Grants.gov)
Letter of
Intent Receipt Date(s): Not applicable
Application Submission Date(s): Standard
dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm for details.
AIDS Application Submission
Date(s): http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS.
Peer Review Date(s): Standard
dates apply, please see http://grants.nih.gov/grants/funding/submissionschedule.htm#reviewandaward for details.
Council Review Date(s) : Standard dates apply, please see http://grants.nih.gov/grants/funding/submissionschedule.htm#reviewandaward for details.
Earliest Anticipated Start Date: Standard dates apply, please see http://grants.nih.gov/grants/funding/submissionschedule.htm#reviewandaward for details.
3.A.1. Letter of Intent
A letter of intent is
not required for the funding opportunity.
3.B. Sending an
Application to the NIH
To submit an application
in response to this FOA, applicants should access this FOA via http://www.grants.gov/Apply and follow
steps 1-4. Note: Applications must only be submitted electronically
PAPER APPLICATIONS WILL NOT BE ACCEPTED.
3.C.
Application Processing
Applications may be submitted to Grants.gov on or
after the opening date and must be
submitted no later than 5:00 p.m. local time (of the applicant institution/organization) on the application submission
date(s). (See Section
IV.3.A. for all dates.) If an application is not submitted by the submission
date(s) and time, the application may be delayed in the review process or not
reviewed.
Upon receipt
applications will be transferred from Grants.gov to the NIH Electronic Research
Administration process for validation. Both the PD/PI and the Signing Official
for the organization must verify the submission via Commons within 2 business days of
notification of the NIH validation.
Upon receipt
applications will be evaluated for completeness by the Center for Scientific
Review, NIH. Incomplete applications will not be reviewed.
The
NIH will not accept any application in response to this FOA that is essentially
the same as one currently pending initial merit review unless the applicant
withdraws the pending application. The NIH will not accept any application that
is essentially the same as one already reviewed. This does not preclude the
submission of an application already reviewed with substantial changes, but
such application must include an Introduction addressing the previous
critique. Note such an application is considered a "resubmission" for
the SF424 (R&R).
There will be an acknowledgement of receipt of
applications from Grants.gov and the Commons. Information related to the
assignment of an application to a Scientific Review Group is also in the Commons.
4. Intergovernmental Review
This initiative is
not subject to intergovernmental
review.
5. Funding Restrictions
All NIH awards are
subject to the terms and conditions, cost principles, and other considerations
described in the NIH Grants Policy Statement
Pre-Award Costs are allowable. A grantee may, at its own
risk and without NIH prior approval, incur obligations and expenditures to
cover costs up to 90 days before the beginning date of the initial budget
period of a new award if such costs: are necessary to conduct the project and
would be allowable under the grant, if awarded, without NIH prior approval. If
specific expenditures would otherwise require prior approval, the grantee must
obtain NIH approval before incurring the cost. NIH prior approval is required
for any costs to be incurred more than 90 days before the beginning date of the
initial budget period of a new award.
The incurrence of
pre-award costs in anticipation of a competing or non-competing award imposes
no obligation on NIH either to make the award or to increase the amount of the
approved budget if an award is made for less than the amount anticipated and is
inadequate to cover the pre-award costs incurred. NIH expects the grantee to be
fully aware that pre-award costs result in borrowing against future support and
that such borrowing must not impair the grantee's ability to accomplish the
project objectives in the approved time frame or in any way adversely affect
the conduct of the project. See the NIH Grants Policy Statement.
6. Other Submission Requirements
The
NIH requires the PD/PI to fill in his/her Commons User ID in the PROFILE
Project Director/Principal Investigator section, Credential log-in field of
the Research & Related Senior/Key Person Profile component. The applicant
organization must include its DUNS number in its Organization Profile in the
eRA Commons. This DUNS number must match the DUNS number provided at CCR registration with Grants.gov. For additional information, see Tips and Tools for Navigating
Electronic Submission on the front page of Electronic Submission of Grant
Applications.
Renewal (formerly competing continuation or Type 2 ) applications are not permitted.
All application instructions outlined in the SF424 (R&R) application are to be followed, with the following requirements for R21 applications:
Note: While each section of the Research Plan needs to be uploaded separately as a PDF attachment, applicants are encouraged to construct the Research Plan as a single document, separating sections into distinct PDF attachments just before uploading the files. This approach will enable applicants to better monitor formatting requirements such as page limits. All attachments must be provided to NIH in PDF format, filenames must be included with no spaces or special characters, and a .pdf extension must be used.
Specific Instructions for Modular Grant applications.
Applications
requesting direct costs in each year of $250,000 or less (excluding consortium
F&A costs), must be submitted in a modular budget format using the Modular
Budget Component provided in the SF424 (R&R) Application Package and
Instructions Guide (see specifically Section 5.4). The modular budget format
simplifies the preparation of the budget in these applications by limiting the
level of budgetary detail. Applicants request direct costs in $25,000 modules.
Plan for
Sharing Research Data
The precise
content of the data-sharing plan will vary, depending on the data being
collected and how the investigator is planning to share the data. Applicants
who are planning to share data may wish to describe briefly the expected
schedule for data sharing, the format of the final dataset, the documentation
to be provided, whether or not any analytic tools also will be provided,
whether or not a data-sharing agreement will be required and, if so, a brief
description of such an agreement (including the criteria for deciding who can receive
the data and whether or not any conditions will be placed on their use), and
the mode of data sharing (e.g., under their own auspices by mailing a disk or
posting data on their institutional or personal website, through a data archive
or enclave). Investigators choosing to share under their own auspices may wish
to enter into a data-sharing agreement. References to data sharing may also be
appropriate in other sections of the application.
The
reasonableness of the data sharing plan or the rationale for not sharing
research data may be assessed by the reviewers. However, reviewers will not
factor the proposed data sharing plan into the determination of scientific
merit or the priority score.
Sharing Research
Resources
Not Applicable
Section
V. Application Review Information
1. Criteria
Only the review
criteria described below will be considered in the review process.
2. Review and Selection Process
Applications
submitted for this funding opportunity will be assigned to the ICs on the basis
of established PHS referral guidelines.
Appropriate scientific review groups convened in accordance with the standard NIH peer review procedures (http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific and technical merit.
As part of the initial merit review, all applications will:
Applications submitted in response to this funding opportunity will compete for available funds with all other recommended applications. The following will be considered in making funding decisions:
The goals of NIH supported research are to advance our understanding of biological systems, to improve the control of disease, and to enhance health. In their written critiques, reviewers will be asked to comment on each of the following criteria in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward.
Significance. Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Approach. Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
Innovation. Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?
Investigators. Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)?
Environment. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?
2.A.
Additional Review Criteria:
In addition to the
above criteria, the following items will continue to be considered in the
determination of scientific merit and the priority score:
Protection
of Human Subjects from Research Risk: The involvement of human subjects and protections from
research risk relating to their participation in the proposed research will be
assessed. See item 6 of the Research Plan component of the SF424 (R&R).
Inclusion
of Women, Minorities and Children in Research: The adequacy of plans to
include subjects from both genders, all racial and ethnic groups (and
subgroups), and children as appropriate for the scientific goals of the
research will be assessed. Plans for the recruitment and retention of subjects
will also be evaluated. See item 7 of the Research Plan component of the SF424
(R&R).
Care and Use of Vertebrate Animals in
Research: If vertebrate animals are to
be used in the project, the five items described under item 11 of the Research
Plan component of the SF424 (R&R) will be assessed.
Biohazards: If materials or procedures are proposed that are
potentially hazardous to research personnel and/or the environment, determine
if the proposed protection is adequate.
2.B. Additional
Review Considerations
Budget: The reasonableness of the proposed
budget and the requested period of support in relation to the proposed research
may be assessed by the reviewers. Is the percent effort listed for the PD/PI
appropriate for the work proposed? Is each budget category realistic and
justified in terms of the aims and methods?
Period of Support: The appropriateness of the
requested period of support in relation to the proposed research.
2.C. Sharing
Research Data
Data Sharing Plan: The reasonableness of the data sharing plan or
the rationale for not sharing research data may be assessed by the reviewers.
However, reviewers will not factor the proposed data sharing plan into the
determination of scientific merit or the priority score. The funding
organization will be responsible for monitoring the data sharing policy. http://grants.nih.gov/grants/policy/data_sharing.
2.D.
Sharing Research Resources
Not
Applicable
3. Anticipated Announcement and Award
Dates
Not Applicable
Section VI. Award Administration Information
1. Award Notices
After the peer review of
the application is completed, the PD/PI will be able to access his or her
Summary Statement (written critique) via the eRA
Commons.
If
the application is under consideration for funding, NIH will request
"just-in-time" information from the applicant. For details,
applicants may refer to the NIH Grants Policy
Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General.
A formal notification in the form of a Notice of Award
(NoA) will be provided to the applicant organization. The NoA signed by the
grants management officer is the authorizing document. Once all administrative
and programmatic issues have been resolved, the NoA will be generated via email
notification from the awarding component to the grantee business official.
Selection of an application for award is not an
authorization to begin performance. Any costs incurred before receipt of the
NoA are at the recipient's risk. These costs may be reimbursed only to the
extent considered allowable pre-award costs. See Also Section
IV.5. Funding Restrictions.
2. Administrative and
National Policy Requirements
All NIH grant and cooperative agreement awards include
the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart
A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm)
and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and
Conditions for Specific Types of Grants, Grantees, and Activities (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).
3. Reporting
When multiple years are involved, awardees will be
required to submit the PHS Non-Competing Grant Progress Report, Form 2590
annually (http://grants.nih.gov/grants/funding/2590/2590.htm)
and financial statements as required in the NIH Grants Policy Statement.
We
encourage your inquiries concerning this funding opportunity and welcome the
opportunity to answer questions from potential applicants. Inquiries may fall
into three areas: scientific/research, peer review, and financial or grants
management issues:
1. Scientific/Research Contacts:
Carl E. Hunt, M.D.
National Center on Sleep Disorders Research
National Heart, Lung, and Blood Institute
6705 Rockledge Drive, 6022
Bethesda, MD 20892-7993
Telephone: (301) 435-0199
Email: [email protected]
Michael Twery, Ph.D.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
6701 Rockledge Drive,10116
Bethesda, MD 20892
Telephone: (301) 435-0202
Email: [email protected]
Andrew A. Monjan, Ph.D., M.P.H.
Neuroscience and Neuropsychology of Aging Program
National Institute on Aging
7201 Wisconsin Avenue, Suite 350
Bethesda, MD 20892-9205
Telephone: (301) 496-9350
Email: [email protected]
Ellen D. Witt, Ph.D.
Division of Neuroscience and Behavior
National Institute on Alcohol Abuse and Alcoholism
5635 Fishers Lane, Room 2063
Bethesda, MD 20892-9304
Telephone: (301) 443-6545
Email: [email protected]
Deborah N. Ader, Ph.D.
Director, Behavioral and Prevention Research Program
National Institute of Arthritis and Musculoskeletal and Skin Diseases
6701 Democracy Blvd., Suite 800
Bethesda, MD 20892
Telephone: (301) 594-5032
Email: [email protected]
Ann O'Mara, Ph.D., R.N.
Program Director, Symptom Management/End of Life
Community Clinical Oncology Program (CCOP)
National Cancer Institute
6130 Executive Blvd., EPN 2010
Bethesda, MD 20892
Telephone: (301) 496-8541
Email: [email protected]
Lynne M. Haverkos, M.D., M.P.H.
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
6100 Executive Blvd. Room 4B05
Bethesda, MD. 20892-7510
Telephone: (301) 435-6881
Email: [email protected]
Nancy Pearson, Ph.D.
National Center for Complementary and Alternative Medicine
6707 Democracy Blvd, Room 401
Bethesda, MD 20892
Telephone: (301) 594-0519
Email: [email protected]
Harold Gordon, Ph.D.
Division of Clinical Neuroscience and Behavioral Research
National Institute on Drug Abuse
6001 Executive Boulevard, Room 4233
Bethesda, MD 20892-9551
Telephone: (301) 443-4877
Email: [email protected]
William T. Riley, Ph.D.
Behavior Change Program Chief
National Institute of Mental Health
6001 Executive Blvd., Room 6226
Bethesda, MD 20892-9615
Telephone: P 301-435-0301
Email: [email protected]
Merrill M. Mitler, Ph.D.
Division of Extramural Research
National Institute of Neurological Disorders and Stroke
6001 Executive Blvd, Room 2116
Bethesda, MD 20892-9521
Telephone: (301) 496-9964
Email: [email protected]
Kathy Mann Koepke, Ph.D.
Division of Extramural Activities
National Institute of Nursing Research
6701 Democracy Blvd, Ste. 710
Bethesda, MD 20892-4870
Telephone: (301) 496-9623
Email: [email protected]
Eleanor Z. Hanna, Ph.D.
Office of Research on Women's Health
Office of the Director
6120 Executive Boulevard, 150A
Bethesda, MD 20892-7116
Telephone: (301) 435-1573
Email: [email protected]
2. Peer Review Contacts:
Not Applicable
3. Financial or Grants Management
Contacts:
Bob Pike
Lung Team Section Chief
Grants Operations Branch
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Room 7152
Bethesda, MD 20892
Telephone (301) 435-0182
Email: [email protected]
Deborah Stauffer
Lead Grants Management Specialist
National Institute on Aging
7201 Wisconsin Ave. Suite 2N212
Bethesda, MD 20892-9205
Telephone: (301) 496-1472
Email: [email protected]
Judy Fox
Chief, Grants Management Branch
National Institute on Alcohol Abuse and Alcoholism
5635 Fishers Lane, Room 3023
Bethesda, MD 20892-9304
Telephone: (301) 443-4704
Email: [email protected]
Melinda Nelson
Grants Management Officer
National Institute of Arthritis and Musculoskeletal and Skin Diseases
6701 Democracy Blvd., Suite 800
Bethesda, MD 20892
Telephone: (301) 594-3535
Email: [email protected]
Ms. Carol Perry
Grants Administration Branch
National Cancer Institute
6120 Executive Boulevard, EPS Room 243
Bethesda, MD 20892-7150
Telephone: (301) 496-7205
Email: [email protected]
Mr. Stuart Tate
Grants Management Branch
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 8A17
Bethesda, MD 20892-7510
Telephone: (301) 435-6999
Email: [email protected]
George Tucker
National Center for Complementary and Alternative Medicine
6707 Democracy Blvd, Suite 401
Bethesda, MD 20892
Telephone: (301) 594 0519
Email: [email protected]
Gary Fleming, J.D.
Chief, Grants Management Branch/OPRM
National Institute on Drug Abuse
6101 Executive Boulevard, Room 270
Bethesda, MD 20892
Telephone: (301) 443-6710
Email: [email protected]
Rebecca D. Claycamp, CRA
Division of Extramural Activities
National Institute of Mental Health
6001 Executive Boulevard, Room 6122
Bethesda, MD 20892-9605
Telephone: (301) 443-2811
Email: [email protected]
Dianna Jessee
Grants Management Branch
National Institute of Neurological Disorders and Stroke
6001 Executive Blvd., Room 3290
Bethesda, MD 20892
Telephone: (301) 496-9231
Email: [email protected]
Diane E. Drew
Grants Management Specialist
National Institute of Nursing Research
6701 Democracy Blvd, Rm. 710
Bethesda, MD 20892-4870
Telephone: (301) 594- 2807
Email: [email protected]
Terri Kendrix
Office of Research on Women's Health
Office of the Director
6120 Executive Boulevard, 150A
Bethesda, MD 20892-7116
Telephone: (301) 435-6724
Email: [email protected]
Section VIII. Other Information
Required Federal Citations
Use of Animals in Research:
Recipients of PHS support for activities involving
live, vertebrate animals must comply with PHS Policy on Humane Care and Use of
Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf)
as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm),
and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm)
as applicable.
Human Subjects Protection:
Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and others,
and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types
of clinical trials, including physiologic toxicity and dose-finding studies
(Phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative
trials (Phase III). Monitoring should be commensurate with risk. The
establishment of data and safety monitoring boards (DSMBs) is required for
multi-site clinical trials involving interventions that entail potential risks
to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants
and Contracts, http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking
$500,000 or more in direct costs in any single year are expected to include a
plan for data sharing or state why this is not possible (http://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their
institutions on issues related to institutional policies and local IRB rules,
as well as local, State and Federal laws and regulations, including the Privacy
Rule. Reviewers will consider the data sharing plan but will not factor the
plan into the determination of scientific merit or the priority score.
Access to Research Data through the Freedom of
Information Act:
The Office of Management and Budget (OMB) Circular
A-110 has been revised to provide access to research data through the Freedom
of Information Act (FOIA) under some circumstances. Data that are (1) first
produced in a project that is supported in whole or in part with Federal funds
and (2) cited publicly and officially by a Federal agency in support of an
action that has the force and effect of law (i.e., a regulation) may be
accessed through FOIA. It is important for applicants to understand the basic
scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this funding opportunity in a
public archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the application.
In addition, applicants should think about how to structure informed consent
statements and other human subjects procedures given the potential for wider
use of data collected under this award.
Sharing of Model Organisms:
NIH is committed to support efforts that encourage
sharing of important research resources including the sharing of model
organisms for biomedical research (see http://grants.nih.gov/grants/policy/model_organism/index.htm).
At the same time the NIH recognizes the rights of grantees and contractors to
elect and retain title to subject inventions developed with Federal funding
pursuant to the Bayh Dole Act (see the NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/index.htm).
All investigators submitting an NIH application or contract proposal, beginning
with the October 1, 2004 receipt date, are expected to include in the
application/proposal a description of a specific plan for sharing and
distributing unique model organism research resources generated using NIH
funding or state why such sharing is restricted or not possible. This will
permit other researchers to benefit from the resources developed with public
funding. The inclusion of a model organism sharing plan is not subject to a
cost threshold in any year and is expected to be included in all applications
where the development of model organisms is anticipated.
Inclusion of Women And Minorities in Clinical
Research:
It is the policy of the NIH that women and members of
minority groups and their sub-populations must be included in all NIH-supported
clinical research projects unless a clear and compelling justification is
provided indicating that inclusion is inappropriate with respect to the health
of the subjects or the purpose of the research. This policy results from the
NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All
investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines is available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the SF424 (R&R); and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a) all
applications or proposals and/or protocols must provide a description of plans
to conduct analyses, as appropriate, to address differences by sex/gender
and/or racial/ethnic groups, including subgroups if applicable; and b)
investigators must report annual accrual and progress in conducting analyses,
as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical
Research:
The NIH maintains a policy that children (i.e.,
individuals under the age of 21) must be included in all clinical research,
conducted or supported by the NIH, unless there are scientific and ethical
reasons not to include them.
All investigators proposing research involving human
subjects should read the "NIH Policy and Guidelines" on the inclusion
of children as participants in research involving human subjects (http://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human
Subject Participants:
NIH policy requires education on the protection of
human subject participants for all investigators submitting NIH applications
for research involving human subjects and individuals designated as key
personnel. The policy is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can
be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html.
Only research using hESC lines that are registered in the NIH Human Embryonic
Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov). It is the responsibility
of the applicant to provide in the project description and elsewhere in the
application as appropriate, the official NIH identifier(s) for the hESC
line(s)to be used in the proposed research. Applications that do not provide
this information will be returned without review.
NIH Public Access Policy:
NIH-funded investigators are requested to submit to
the NIH manuscript submission (NIHMS) system (http://www.nihms.nih.gov)
at PubMed Central (PMC) an electronic version of the author's final manuscript
upon acceptance for publication, resulting from research supported in whole or
in part with direct costs from NIH. The author's final manuscript is defined as
the final version accepted for journal publication, and includes all
modifications from the publishing peer review process.
NIH is requesting that authors submit manuscripts
resulting from 1) currently funded NIH research projects or 2) previously
supported NIH research projects if they are accepted for publication on or
after May 2, 2005. The NIH Public Access Policy applies to all research grant
and career development award mechanisms, cooperative agreements, contracts,
Institutional and Individual Ruth L. Kirschstein National Research Service
Awards, as well as NIH intramural research studies. The Policy applies to
peer-reviewed, original research publications that have been supported in whole
or in part with direct costs from NIH, but it does not apply to book chapters,
editorials, reviews, or conference proceedings. Publications resulting from
non-NIH-supported research projects should not be submitted.
For more information about the Policy or the
submission process please visit the NIH Public Access Policy Web site at http://PublicAccess.nih.gov/ and
view the Policy or other Resources and Tools including the Authors' Manual (http://publicaccess.nih.gov/publicaccess_manual.htm).
Standards for Privacy of Individually Identifiable
Health Information:
The Department of Health and Human Services (DHHS)
issued final modification to the "Standards for Privacy of Individually
Identifiable Health Information", the "Privacy Rule", on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance
Portability and Accountability Act (HIPAA) of 1996 that governs the protection
of individually identifiable health information, and is administered and
enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of
the Privacy Rule reside with the researcher and his/her institution. The OCR
Website (http://www.hhs.gov/ocr/)
provides information on the Privacy Rule, including a complete Regulation Text
and a set of decision tools on "Am I a covered entity?" Information
on the impact of the HIPAA Privacy Rule on NIH processes involving the review,
funding, and progress monitoring of grants, cooperative agreements, and
research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be
self-contained within specified page limitations. Unless otherwise specified in
an NIH solicitation, Internet addresses (URLs) should not be used to provide
information necessary to the review because reviewers are under no obligation
to view the Internet sites. Furthermore, we caution reviewers that their
anonymity may be compromised when they directly access an Internet site.
Healthy People 2010:
The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of
"Healthy People 2010," a PHS-led national activity for setting
priority areas. This FOA is related to one or more of the priority areas.
Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This
program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections 301
and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and
under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All awards are
subject to the terms and conditions, cost principles, and other considerations
described in the NIH Grants Policy Statement. The NIH Grants Policy
Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to
provide a smoke-free workplace and discourage the use of all tobacco products.
In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits
smoking in certain facilities (or in some cases, any portion of a facility) in
which regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan
repayment from qualified health professionals who have made a commitment to
pursue a research career involving clinical, pediatric, contraception,
infertility, and health disparities related areas. The LRP is an important
component of NIH's efforts to recruit and retain the next generation of
researchers by providing the means for developing a research career unfettered
by the burden of student loan debt. Note that an NIH grant is not required for
eligibility and concurrent career award and LRP applications are encouraged.
The periods of career award and LRP award may overlap providing the LRP
recipient with the required commitment of time and effort, as LRP awardees must
commit at least 50% of their time (at least 20 hours per week based on a 40
hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||